Q-Line Biotech FY26 PAT rises 190%, EBITDA margin expands to 28.7%
Q-Line Biotech Limited reported a 190% surge in FY26 PAT to ₹5,572 lakh, with EBITDA margin expanding to 28.7% on a 9% revenue rise to ₹34,174 lakh. Growth was driven by a 70% increase in manufactured reagent sales and margin expansion. The company also disclosed the audio recording of its June 23, 2026 earnings call to the NSE.
*this image is generated using AI for illustrative purposes only.
Q-Line Biotech Limited reported a 190% year-on-year increase in profit after tax (PAT) to ₹5,572 lakh for FY26, driven by significant margin expansion and a strategic focus on in-house manufacturing. The company’s EBITDA margin improved to 28.7% from 22.5% in the previous year, supported by strong growth in high-margin domestically manufactured reagents and favorable product mix. Revenue from operations for the year grew 9% to ₹34,174 lakh.
The financial performance reflects a transformative year for the company, marked by the successful capitalization of its largest manufacturing facility in Lucknow. Sales of manufactured reagents increased by nearly 70% during the year, accounting for 69.8% of total revenue. This shift towards higher-value products and operating leverage contributed to a gross profit margin expansion of 747 basis points to 60.8%.
Operational Highlights
Q-Line Biotech achieved a key milestone in its instruments division, reaching an installed base of over 1,550 Selectra Pro M Fully Automatic Biochemistry Analysers. The company also commercialized its Electrolyte Analyzer and is on track to launch the Micro lab 300 by Q2 FY27. Additionally, Unit 4, commissioned in February 2026, has obtained licenses for five products, with commercial production of Clinical Chemistry Reagents expected by Q2 FY27 subject to regulatory clearances.
Consolidated Financial Performance
| Particulars (Rs lakhs) | FY26 | FY25 | Y-o-Y |
|---|---|---|---|
| Net Revenue from Operations | 34,174 | 31,314 | 9% |
| Gross Profit | 20,763 | 16,686 | 24% |
| Gross Profit Margin (%) | 60.8% | 53.3% | 747 bps |
| EBITDA | 9,805 | 7,055 | 39% |
| EBITDA Margin (%) | 28.7% | 22.5% | 616 bps |
| PAT | 5,572 | 1,921 | 190% |
| PAT Margin (%) | 16.3% | 6.1% | 1017 bps |
Strategic Developments
The company is expanding its international footprint, having signed distributor agreements across 8 countries. Export revenue reached ₹1.18 Cr in FY26, with expectations to grow approximately 5x in FY27. Q-Line Biotech is also planning to commence Contract Development and Manufacturing Organization (CDMO) operations through the manufacturing of Selectra Pro M and Microlab 300 instruments for export under an exclusive technical collaboration arrangement.
Governance and digital transformation initiatives are underway, with PwC engaged to enhance IFC and ICFR frameworks. An ERP implementation is currently in progress, with a full rollout targeted by the end of FY27 to strengthen process automation and data-driven decision-making.
Regulatory Disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Q-Line Biotech Limited submitted the audio recording of its Earnings Conference Call held on June 23, 2026. The recording has been made available on the company's website. Managing Director Saurabh Garg signed the disclosure submitted to the National Stock Exchange of India Limited (NSE) on June 23, 2026.
How will the planned commencement of CDMO operations impact the company's revenue diversification and margin profile in FY27?
What specific market risks or regulatory hurdles could potentially delay the commercial production of Clinical Chemistry Reagents at Unit 4?
Can the 70% growth in manufactured reagent sales be sustained as the revenue mix approaches saturation with domestically manufactured products?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
